Biotech
A published application from Stryker Corporation claims a method that turns intraoperative fluorescence imagery into a simulated photograph of how tissue is expected to look after surgery. Read alongside the rest of its recent publication cohort, it suggests the imaging franchise is being extended from what a surgeon can see to what a surgeon can anticipate.
Biotech
A patent issued July 21 covers using methylation-altering SNPs to flag cell-free DNA fragments that came from someone other than the patient, and to withhold the sample from cancer classification. The issued claim and the specification describe the threshold test in opposite terms.
Biotech
A published application assigned to Edwards Lifesciences Corporation claims implantation methods that seat the whole valve frame between the annulus and the sinotubular junction — and one independent claim starts by measuring the gap before a valve is chosen.
Biotech
A published application from the 2026-07-16 drop claims a conjugate that carries GLP-1 receptor agonist payloads on an anti-GDF8 antibody, plus the enzymatic site-specific chemistry used to build it. Murphy and Yancopoulos are named inventors.
Biotech
A July 7 Rice University grant threads a microelectrode catheter to neural targets through the subarachnoid space and powers it magnetoelectrically. With two same-week grants, it maps a university bioengineering estate.
Biotech
A July 7 Pacesetter grant detects implant migration from accelerometer posture data — a device that reads 'lying down' while the patient stands has rotated. The same-week cohort maps a leadless-pacemaker instrumentation estate.
Biotech
A July 7 grant lets an energy-harvesting implant detect a failing harvester from accelerometer data and cut its own power use. Alongside five same-week grants, it maps a device-instrumentation and power-management estate.
Biotech
Biosense Webster published nine electrophysiology-catheter applications on July 2, clustered around pulsed field ablation tips with integrated mapping and flexible-circuit construction — a disclosure of where its device engineering is concentrated.
Biotech
A July 2 Form S-1 registers an in-vivo CRISPR company's proposed listing under the ticker SCTX. The proceeds figure, share count, and price are all placeholders; the use-of-proceeds language and pipeline status are on the record.
Biotech
Nuvectis, Abivax, Neurogene and Biodexa each filed a 424B5 dated June 30 to sell equity. Nuvectis priced a $100 million underwritten block at $20.00 a share; the others used ADS takedowns, pre-funded warrants and a warrant inducement. A capital-structure read of the wave.
Biotech
Five patents issued to Medtronic entities on June 30 span imaging reconstruction, an implantable lead, renal neuromodulation hardware, computational planning, and bioelectric sensing. Read together, the cluster signals where the company is aiming its interventional-device engineering.
Biotech
An 8-K filed June 29 lays out the merger agreement: $17.00 cash per Theravance ordinary share, one contingent value right tied to ampreloxetine, up to $350 million in committed debt, and matching $32.515 million break fees. Here is the disclosed structure, term by term.
Biotech
An 8-K filed June 23, 2026 discloses that Sangamo Therapeutics entered Chapter 11 in Delaware and signed a stalking-horse asset purchase agreement under which an Eli Lilly subsidiary would acquire its technology platforms for $50 million, subject to higher bids and court approval.
Biotech
When a biotech says there is "substantial doubt about its ability to continue as a going concern," that is a defined accounting disclosure, not loose language. Here is what ASC 205-40 requires, read from a real 10-Q.
Biotech
"Runway" is how many quarters a company can fund itself before it needs more money. Here is how to compute it from the cash position and burn rate disclosed in a 10-Q or 8-K — with a real worked example.
Biotech
Whether an 8-K disclosure is "filed" or "furnished" changes its legal liability status — and the difference is built into Items 2.02 and 8.01. Here is what the SEC's instructions actually say.
Biotech
Some collaborations let the smaller partner choose between collecting royalties and sharing profits — a built-in switch over a program's economics. Here is how opt-in profit-shares and option-to-license structures work, read from a real SEC filing.
Biotech
"Tiered royalties on net sales" is the third economic layer of a licensing deal, after the upfront and the milestones. Here is what the phrase means, how step-ups and step-downs work, and how it is disclosed.
Biotech
A CVR lets an acquirer pay part of the price only if a future milestone is met, splitting a deal into cash now plus a conditional promise. Here is how the structure is disclosed, read against a real merger agreement filed with the SEC.
Biotech
Item 1.01 is the line on a Form 8-K that tells the market a company has signed a material deal outside the ordinary course of business. Here is exactly what it requires a registrant to disclose, straight from the SEC's General Instructions.
Biotech
A headline deal value of "up to $2.2 billion" is mostly contingent milestone payments, not cash in hand. Here is how upfronts, biobucks, and tiered royalties are structured and disclosed, read against a real SEC-filed collaboration.
Biotech
Provectus Biopharmaceuticals filed a Form 8-K on June 18, 2026, furnishing its annual stockholder-meeting presentation under Regulation FD as Exhibit 99.1.
Biotech
A Federal Register notice published June 18, 2026 announces two FDA Emergency Use Authorizations for animal products to prevent and treat New World screwworm myiasis, requested by Health and Hygiene (Pty) Ltd. and Elanco US Inc.
Biotech
Intuitive Surgical's June 18 published application on machine learning for robotic medical systems lands inside a cluster of recent filings that read the operating room as a data stream, not just a set of instruments.
